Related Experiment Video
Updated: Jan 10, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Targeting Non-BET Bromodomains: Emerging Opportunities in Drug Discovery
Huili Li1,2, Fei Jiang1,2, Quan Sun1,2
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Gui'an New District, Guiyang, Guizhou 561113, P.R. China.
Abstract:
Bromodomains, epigenetic "readers" of acetylated lysine marks, represent promising therapeutic targets. The clinical limitations of BET inhibitors, together with growing insights into the distinct functions of non-BET members (e.g., ATAD2, CBP/p300, and BRD7/9), highlight the importance of pursuing their pharmacological potential. This Perspective examines recent medicinal chemistry advances in the development of non-BET bromodomain inhibitors, focusing on structure-guided strategies to address selectivity challenges within conserved KAc-binding pockets. Key topics include: (1) the structural and functional diversity of non-BET bromodomains in oncology, inflammation, and metabolic diseases; (2) innovative design strategies, such as allosteric covalent modulation and the development of PROTACs and other heterobifunctional molecules; and (3) preclinical/clinical progress of leads targeting CBP/p300, BRD7/9, and SMARCA2/4. Pharmacokinetic challenges (e.g., blood-brain barrier penetration, tissue-specific delivery) and opportunities in AI-driven discovery and nonepigenetic synergies are evaluated. By integrating mechanistic insights with medicinal chemistry breakthroughs, this Perspective aims to inform the rational development of selective non-BET bromodomain modulators with enhanced therapeutic potential.
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug-Receptor Bonds
In...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Targeted Cancer Therapies
There are several types of targeted therapies against...

